Up To $330M CAD ($324 Million USD) International Partnership Between Bayer HealthCare Pharmaceuticals And EndoCeutics

Published: Oct 05, 2010

QUÉBEC, Oct 5 /CNW Telbec/ - Bayer HealthCare Pharmaceuticals (Bayer) and EndoCeutics Inc., Québec, are proud to announce the signing of an exclusive international collaborative agreement for Phase III development and marketing of Dehydroepiandrosterone (DHEA), a new treatment for vaginal atrophy and female sexual dysfunction.

Back to news